Physician profile
William Alvarez
NPI 1619967528
$8,160.96
in general payments reported to CMS, 2019-2025
31 companies · $745 in 2025
The $745 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $1,307 · 2021: $1,862 · 2022: $1,214 · 2023: $1,275 · 2024: $1,173 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,175 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,174.94 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,653.81 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,158.19 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $767.86 | 2021-2024 | Ubrelvy |
| Lilly USA, LLC | $755.44 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Glaxosmithkline, LLC. | $423.71 | 2019-2025 | Trelegy Ellipta |
| Esperion Therapeutics, INC. | $321.02 | 2022-2025 | Nexletol, Nexlizet |
| Boehringer Ingelheim Pharmaceuticals, INC. | $314.54 | 2019-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $314.03 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $303.11 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $277.28 | 2021-2025 | |
| Pfizer INC. | $253.33 | 2019-2025 | |
| Allergan, INC. | $215.44 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $164.94 | 2022 | |
| Amgen INC. | $163.60 | 2020-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $154.83 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $129.03 | 2019-2021 | |
| Amarin Pharma, INC. | $122.96 | 2020 | |
| Idorsia Pharmaceuticals US INC | $121.30 | 2022-2024 | Quviviq |
| Exact Sciences Corporation | $111.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $102.11 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $57.09 | 2020 | |
| Azurity Pharmaceuticals, INC. | $56.15 | 2024-2025 | |
| Inspire Medical Systems, INC. | $50.43 | 2024 | Inspire |
| Insmed, INC. | $47.06 | 2025 | Brinsupri, Arikayce |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.73 | 2019 | |
| Hikma Pharmaceuticals USA | $21.21 | 2021 | |
| Eyevance Pharmaceuticals LLC | $21.21 | 2021 | |
| Horizon Therapeutics Plc | $16.20 | 2023 | Krystexxa |
| Corcept Therapeutics | $14.68 | 2025 | Korlym |
| Seqirus USA INC | $14.38 | 2019 | |
| Ironshore Pharmaceuticals INC. | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.